Barron's: Regeneron Shares Poised for Rebound

Barron's: Regeneron Shares Poised for Rebound


Shares of Regeneron Pharmaceuticals Inc., which tumbled 32 percent in 2016, are poised for a rebound, the financial newspaper Barron's said. A better-than-expected launch of Regeneron's skin treatment Dupixent caused shares to soar last week, the paper reported in its May 8 edition.



from Biotech News